About Wegovy™

**Wegovy™** (semaglutide) injection 2.4 mg

**Overview**

Wegovy™ is a GLP-1 analogue used for chronic weight management.

**Indication**

Wegovy™ is indicated for adults with obesity who need weight loss and whose weight loss history includes both diet and exercise.

**Dosage and Administration**

Wegovy™ is administered subcutaneously once a week using a prefilled pen. 

**Warnings and Precautions**

**Side Effects**

- The most common side effects of Wegovy™ may include:
  - Nausea
  - Diarrhea
  - Vomiting
  - Constipation
  - Abdominal pain
- Increased risk of low blood sugar (hypoglycemia) in patients with type 2 diabetes, especially those who also take sulfonylureas or insulin.

**Contraindications**

- Do not use Wegovy™ if:
  - You have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy™.
  - You or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). Wegovy™ may cause medullary thyroid carcinoma (MTC) in people.
  - It is not known if Wegovy™ can be used safely in people with a history of pancreatitis.
  - It is not known if Wegovy™ is safe and effective when taken with other prescription, over-the-counter, or herbal medicines, vitamins, and herbal supplements.

**Drug Interactions**

- Wegovy™ slows stomach emptying and can affect medicines that need to pass through the stomach and into the intestine. Wegovy™ may affect the way some medicines work and some medicines may affect the way Wegovy™ works.

**Precautions**

- **Obesity:** In overweight and obese patients, the use of weight loss products or other weight loss therapies is associated with a higher risk of serious or life-threatening adverse outcomes, including death, cardiovascular death, and cardiovascular events (MYOCARDIAL INFARCTION [MI] and/or OEDEMA) in people who are at risk for or who have obesity-related medical conditions, including diabetes. In the STEP trials, nausea, diaphoresis, vomiting, and abdominal pain were the most frequent reported adverse events. During treatment with Wegovy™, the most frequent reported adverse events were nausea, diarrhea, vomiting, constipation, and abdominal pain.

**References**

4. 5. Important Safety Information and Medication Guide.

**Wegovy™** is a trademark of Novo Nordisk A/S.